The P38α rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non–Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy-Reference-Cited by-同舟云学术

The P38α rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non–Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy

Published:2016-12 Issue:6 Volume:9 Page:531-539
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Jia Ming,Xu Yuan,Zhu Meiling,Wang Mengyun,Sun Menghong,Qian Ji,Chang Jianhua,Wei Qingyi

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference38 articles.

1. Epidemiology: the dominant malignancy;Bender;Nature,2014

2. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2016

3. Validation of the proposed International Association for the Study of Lung Cancer non–small cell lung cancer staging system revisions for advanced bronchioloalveolar carcinoma using data from the California Cancer Registry;Zell;J Thorac Oncol,2007

4. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non–small cell lung cancer;Yang;Cochrane Database Syst Rev,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and future prospects of p38α/MAPK14 kinase and its inhibitors;European Journal of Medicinal Chemistry;2021-03

2. An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy;International Journal of Cancer;2017-11-24

3. Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy;Scientific Reports;2017-09-06